2023
Applications of CRISPR technology in cellular immunotherapy
Zhou X, Renauer P, Zhou L, Fang S, Chen S. Applications of CRISPR technology in cellular immunotherapy. Immunological Reviews 2023, 320: 199-216. PMID: 37449673, PMCID: PMC10787818, DOI: 10.1111/imr.13241.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMassively parallel knock-in engineering of human T cells
Dai X, Park J, Du Y, Na Z, Lam S, Chow R, Renauer P, Gu J, Xin S, Chu Z, Liao C, Clark P, Zhao H, Slavoff S, Chen S. Massively parallel knock-in engineering of human T cells. Nature Biotechnology 2023, 41: 1239-1255. PMID: 36702900, PMCID: PMC11260498, DOI: 10.1038/s41587-022-01639-x.Peer-Reviewed Original Research
2022
Genome Engineering for Next-Generation Cellular Immunotherapies
Park JJ, Lee KAV, Lam SZ, Tang K, Chen S. Genome Engineering for Next-Generation Cellular Immunotherapies. Biochemistry 2022, 62: 3455-3464. PMID: 35930700, PMCID: PMC11320893, DOI: 10.1021/acs.biochem.2c00340.Peer-Reviewed Original ResearchConceptsGenome engineeringCellular immunotherapySynthetic biology approachesKnockout of genesGenome engineering approachesGenetic screening approachCell therapyNK cell therapyCAR-NK cellsBiology approachHost-graft interactionsNovel target discoveryLong-term persistenceImmune cell typesCRISPR-CasFuture therapeutic developmentTarget discoveryGenetic modificationCell typesAllogeneic contextTumor effect
2021
Tumor immunology CRISPR screening: present, past, and future
Dong MB, Tang K, Zhou X, Zhou JJ, Chen S. Tumor immunology CRISPR screening: present, past, and future. Trends In Cancer 2021, 8: 210-225. PMID: 34920978, PMCID: PMC8854335, DOI: 10.1016/j.trecan.2021.11.009.Peer-Reviewed Original Research
2020
A web tool for the design of prime-editing guide RNAs
Chow RD, Chen JS, Shen J, Chen S. A web tool for the design of prime-editing guide RNAs. Nature Biomedical Engineering 2020, 5: 190-194. PMID: 32989284, PMCID: PMC7882013, DOI: 10.1038/s41551-020-00622-8.Peer-Reviewed Original Research
2019
In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma
Ye L, Park JJ, Dong MB, Yang Q, Chow RD, Peng L, Du Y, Guo J, Dai X, Wang G, Errami Y, Chen S. In vivo CRISPR screening in CD8 T cells with AAV–Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nature Biotechnology 2019, 37: 1302-1313. PMID: 31548728, PMCID: PMC6834896, DOI: 10.1038/s41587-019-0246-4.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDCD8-Positive T-LymphocytesCell Line, TumorCRISPR-Cas SystemsDependovirusFemaleGene EditingGlioblastomaHumansImmunotherapy, AdoptiveLymphocyte Activation Gene 3 ProteinMaleMembrane ProteinsMiceN-AcetylglucosaminyltransferasesNeoplasm ProteinsProtein Disulfide-IsomerasesReceptors, Cell SurfaceRNA, Guide, CRISPR-Cas SystemsTransposasesXenograft Model Antitumor AssaysConceptsRNA cassetteMembrane protein targetsPrimary murine T cellsGenetic screening systemSingle-cell sequencingScreen hitsSleeping Beauty (SB) transposonCRISPR screensMembrane proteinsCell sequencingT cellsAdeno-associated virusGenomic integrationMembrane targetsMurine T cellsProtein targetsEfficient geneHuman GBM cellsGene editingT cell receptor transgenic modelGBM cellsBeauty transposonPDIA3T cell-based immunotherapyAntigen-specific killingIn vivo profiling of metastatic double knockouts through CRISPR–Cpf1 screens
Chow RD, Wang G, Ye L, Codina A, Kim HR, Shen L, Dong MB, Errami Y, Chen S. In vivo profiling of metastatic double knockouts through CRISPR–Cpf1 screens. Nature Methods 2019, 16: 405-408. PMID: 30962622, PMCID: PMC6592845, DOI: 10.1038/s41592-019-0371-5.Peer-Reviewed Original ResearchOne-step generation of modular CAR-T cells with AAV–Cpf1
Dai X, Park JJ, Du Y, Kim HR, Wang G, Errami Y, Chen S. One-step generation of modular CAR-T cells with AAV–Cpf1. Nature Methods 2019, 16: 247-254. PMID: 30804551, PMCID: PMC6519746, DOI: 10.1038/s41592-019-0329-7.Peer-Reviewed Original Research
2018
Cancer CRISPR Screens In Vivo
Chow RD, Chen S. Cancer CRISPR Screens In Vivo. Trends In Cancer 2018, 4: 349-358. PMID: 29709259, PMCID: PMC5935117, DOI: 10.1016/j.trecan.2018.03.002.Books
2017
Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications
Pyzocha NK, Chen S. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications. ACS Chemical Biology 2017, 13: 347-356. PMID: 29121460, PMCID: PMC6768076, DOI: 10.1021/acschembio.7b00800.Peer-Reviewed Original ResearchConceptsGenome engineering applicationsCRISPR-Cas genome editing technologiesMicrobial adaptive immune systemGenome editing technologyEffector enzymeNucleic acid cleavageEditing technologyUnique propertiesModern molecular biologyEngineering applicationsEffector proteinsMammalian cellsMolecular biologyAdaptive immune systemWide diversityTechnologyEnzymeApplicationsFunctionalityAcid cleavageImmune systemBiologyProteinDNADiversity
2014
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology 2014, 32: 551-553. PMID: 24681508, PMCID: PMC4157757, DOI: 10.1038/nbt.2884.Peer-Reviewed Original Research